Opdivo in combo with Yervoy for Metastatic Melanoma – Details


( Last Updated : December 18, 2017)
Generic Name:
Nivolumab & Ipilimumab in combo
Project Status:
Complete
Therapeutic Area:
Metastatic Melanoma
Manufacturer:
Bristol-Myers Squibb Canada
Brand Name:
Opdivo & Yervoy in combo
Project Line:
Reimbursement Review
Project Number:
PC0098-000
NOC Date:

Details


Strength:
40 mg & 100 mg single-use vials
Tumour Type:
Skin and Melanoma
Indications:
Metastatic Melanoma
Funding Request:
In combination, for treatment-naïve adult patients with advanced (unresectable or metastatic) melanoma, regardless of BRAF status
Review Status:
Complete
Sponsor:
Bristol-Myers Squibb Canada
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Not Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Clarification:
The pCODR Expert Review Committee (pERC) Recommendation was deferred on April 20, 2017 pending additional information from the submitter. The timeline of the review has resumed as the additional information has now been provided and a new pERC date has been set by pCODR.
Funding Request:
In combination, for treatment-naïve adult patients with advanced (unresectable or metastatic) melanoma, regardless of BRAF status
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.